Table 1 Gag epitope coverage requirements of all possible formulations of the four natural sequence based products for the global group M dataset.
Natural Sequence Construct | Minimum number of T Cell Epitopes Required to Reach Indicated Coverage of Group M Gag Dataset | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | 1-Hit Model | 2-Hit Model | 3-Hit Model | ||||||
| Â | 95% | 90% | 75% | 95% | 90% | 75% | 95% | 90% | 75% |
Mono-valent MVA-KEA (A) | 13 | 10 | 6 | 20 | 17 | 12 | > 20 | > 20 | 18 |
Mono-valent MVA-TZC (C) | 9 | 7 | 4 | 14 | 12 | 8 | 19 | 16 | 12 |
Mono-valent MVA-UGD (D) | 10 | 8 | 5 | 16 | 14 | 10 | > 20 | 19 | 14 |
Mono-valent MVA-CMDR (E) | 12 | 9 | 6 | 19 | 15 | 11 | > 20 | > 20 | 16 |
Di-valent KEA/TZC (AC) | 6 | 5 | 3 | 10 | 9 | 6 | 14 | 12 | 9 |
Di-valent KEA/UGD (AD) | 7 | 6 | 4 | 12 | 10 | 7 | 16 | 14 | 11 |
Di-valent KEA/CMDR (AE) | 9 | 7 | 4 | 14 | 12 | 8 | 19 | 16 | 12 |
Di-valent TZC/UGD (CD) | 6 | 5 | 3 | 10 | 8 | 6 | 13 | 11 | 9 |
Di-valent TZC/CMDR (CE) | 6 | 5 | 3 | 10 | 8 | 6 | 13 | 12 | 9 |
Di-valent UGD/CMDR (DE) | 7 | 6 | 4 | 12 | 10 | 7 | 16 | 14 | 11 |
Tri-valent KEA/TZC/UGD (ACD) | 5 | 4 | 3 | 9 | 7 | 5 | 12 | 10 | 8 |
Tri-valent KEA/TZC/CMDR (ACE) | 6 | 4 | 3 | 9 | 8 | 6 | 12 | 11 | 8 |
Tri-valent KEA/UGD/CMDR (ADE) | 6 | 5 | 3 | 11 | 9 | 6 | 14 | 12 | 9 |
Tri-valent TZC/UGD/CMDR (CDE) | 5 | 4 | 3 | 9 | 7 | 5 | 12 | 10 | 8 |
Tetra-valent KEA/TZC/UGD/CMDR (ACDE) | 5 | 4 | 3 | 8 | 7 | 5 | 11 | 10 | 7 |